BigHat Biosciences designs safer, more effective antibody therapies for patients using machine learning and synthetic biology.
Mission
Our MillinerTM platform integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies.
We apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
01.
Antibody Discovery & Engineering
Full-stack antibody discovery and engineering
BigHat’s Milliner platform integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform.
02.
Better Antibodies Faster
Better antibodies faster
Hundreds of recombinant antibodies can be synthesized, purified, and fully characterized for biophysics and function in a single, weekly workcell.
03.
Targeting Intractable Diseases
For today’s most challenging diseases
Antibodies are some of the most powerful and successful medicines for diseases from infections to cancers. Next-generation therapies promise greater safety and efficacy for patients with rational molecular design.
company
Who we are
At BigHat, we have a high-performance culture of excellence, but also pride ourselves on our work/life balance and family-friendly culture.
We’re a Series B biotech outside San Francisco with a pipeline of wholly-owned and partnered therapeutic programs. We’ve raised >$100M from top investors to pursue our vision to create safer, more effective antibody therapies for patients using machine learning and synthetic biology.
